Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Ibrutinib in Advanced Refractory Colorectal Cancer
NCT03332498Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in colorectal cancer (CRC), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase II Dose at 42 days and Disease Control Rate at 4 months. Started Jan 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03332498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332498.